Barinthus Biotherapeutics Statistics
Total Valuation
BRNS has a market cap or net worth of $38.02 million. The enterprise value is -$57.10 million.
Important Dates
The last earnings date was Wednesday, November 6, 2024, before market open.
Earnings Date | Nov 6, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
BRNS has 40.23 million shares outstanding. The number of shares has increased by 2.31% in one year.
Current Share Class | n/a |
Shares Outstanding | 40.23M |
Shares Change (YoY) | +2.31% |
Shares Change (QoQ) | +0.97% |
Owned by Insiders (%) | 7.73% |
Owned by Institutions (%) | 26.02% |
Float | 28.17M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 2.34 |
Forward PS | n/a |
PB Ratio | 0.22 |
P/TBV Ratio | 0.29 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.93, with a Debt / Equity ratio of 0.08.
Current Ratio | 8.93 |
Quick Ratio | 8.43 |
Debt / Equity | 0.08 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -1,301.04 |
Financial Efficiency
Return on equity (ROE) is -32.60% and return on invested capital (ROIC) is -20.52%.
Return on Equity (ROE) | -32.60% |
Return on Assets (ROA) | -18.65% |
Return on Capital (ROIC) | -20.52% |
Revenue Per Employee | $115,146 |
Profits Per Employee | -$444,823 |
Employee Count | 130 |
Asset Turnover | 0.07 |
Inventory Turnover | n/a |
Taxes
Income Tax | -867,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -67.31% in the last 52 weeks. The beta is -0.58, so BRNS's price volatility has been lower than the market average.
Beta (5Y) | -0.58 |
52-Week Price Change | -67.31% |
50-Day Moving Average | 1.27 |
200-Day Moving Average | 1.85 |
Relative Strength Index (RSI) | 30.96 |
Average Volume (20 Days) | 46,438 |
Short Selling Information
Short Interest | 8,360 |
Short Previous Month | 3,975 |
Short % of Shares Out | 0.03% |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.17 |
Income Statement
In the last 12 months, BRNS had revenue of $14.97 million and -$57.83 million in losses. Loss per share was -$1.49.
Revenue | 14.97M |
Gross Profit | -30.12M |
Operating Income | -62.45M |
Pretax Income | -65.25M |
Net Income | -57.83M |
EBITDA | -59.84M |
EBIT | -62.45M |
Loss Per Share | -$1.49 |
Full Income Statement Balance Sheet
The company has $106.10 million in cash and $12.67 million in debt, giving a net cash position of $93.43 million or $2.32 per share.
Cash & Cash Equivalents | 106.10M |
Total Debt | 12.67M |
Net Cash | 93.43M |
Net Cash Per Share | $2.32 |
Equity (Book Value) | 159.46M |
Book Value Per Share | 4.03 |
Working Capital | 119.58M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$61.63 million and capital expenditures -$461,000, giving a free cash flow of -$62.09 million.
Operating Cash Flow | -61.63M |
Capital Expenditures | -461,000 |
Free Cash Flow | -62.09M |
FCF Per Share | -$1.54 |
Full Cash Flow Statement Margins
Gross Margin | -201.19% |
Operating Margin | -417.20% |
Pretax Margin | -392.47% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
BRNS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.31% |
Shareholder Yield | -2.31% |
Earnings Yield | -159.90% |
FCF Yield | -171.68% |
Analyst Forecast
The average price target for BRNS is $4.00, which is 323.28% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $4.00 |
Price Target Difference | 323.28% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
BRNS has an Altman Z-Score of 0.08 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.08 |
Piotroski F-Score | 1 |